Evidence map›Paper›PMID 30252597›Full record

ArticleCancer biology & therapy2018

FOXD4 induces tumor progression in colorectal cancer by regulation of the SNAI3/CDH1 axis.

Cheng Chen, Maimaiti Aihemaiti, Xin Zhang, Hui Qu, Jie Jiao, Qilong Sun, Wenbin Yu

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Analysis of the Effect of SNAI Family in Breast Cancer and Immune Cell.Frontiers in cell and developmental biology · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Diagnostic and prognostic values of forkhead box D4 gene in colonic adenocarcinoma.International journal of clinical and experimental pathology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cheng Chena Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Maimaiti Aihemaitia Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Xin Zhanga Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Hui Qua Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Jie Jiaoa Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Qilong Suna Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Wenbin Yua Department of General Surgery , Qilu Hospital of Shandong University , JiNan , China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is ranked third as the most common malignancy, and it develops into metastasis at a high rate. Importantly, distant metastasis is considered to be a key factor for colorectal therapy. In the present study, we identified FOXD4, a transcription factor belonging to the forkhead/winged helix-box (FOX) family, as a novel biomarker for diagnosis and treatment of patients with CRC. We revealed that FOXD4 was up-regulated in CRC tissues and increased the metastatic ability of CRC cells. Additionally, FOXD4 affected the metastasis of CRC by inducing the epithelial-mesenchymal transition (EMT) process. Furthermore, FOXD4 could directly bind the SNAI3 promoter during EMT in CRC and then facilitate CRC metastasis. In summary, the present research strongly suggests that FOXD4 is a valuable marker for CRC, and that targeting FOXD4 may be a novel strategy for enhancing the treatment outcomes of CRC therapy.

Indexed as

cancer biologyCDH1colorectal cancerepithelial-mesenchymal transitionFOXD4metastasisSNAI3transcription factor

Identifiers

PMID30252597
PMCPMC6301805
OpenAlexW2893936927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.